reports
Savara to Present at the H.C. Wainwright 25th Annual Global Investment...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 at 3:30pm ET/12:30pm PT. A live webcast of the presentation will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macroph...
- Jonathan Moreland
LPSN LIVEPERSON INC.
INTC INTEL CORPORATION
HRTX HERON THERAPEUTICS INC
GGG GRACO INC.
FFIN FIRST FINANCIAL BANKSHARES INC
CROX CROCS INC.
AQMS AQUA METALS INC
ACTG ACACIA RESEARCH CORP. - ACACIA TECHNOLOGIES
ADC AGREE REALTY CORPORATION
CULP CULP INC.
CNA CNA FINANCIAL CORPORATION
NTIC NORTHERN TECHNOLOGIES INTERNATIONAL
FBK FB FINANCIAL CORPORATION
XOM EXXON MOBIL CORPORATION
SNAP SNAP INC. CLASS A
SVRA SAVARA
GNTY GUARANTY BANCSHARES INC.
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
VBIV VBI VACCINES INC/BC
TDW TIDEWATER INC
ILPT INDUSTRIAL LOGISTICS
ZM ZOOM VIDEO COMMUNICATIONS
PAYS INC.
QMCO PAYSIGN INC
ENX QUANTUM CORP /DE/
ZI EATON VANCE NEW YORK MUNICIPAL BOND FUND
AWH ZOOMINFO TECHNOLOGIES INC.
RILY ASPIRA WOMEN'S HEALTH INC.
INZY B. RILEY FINANCIAL
HPK INOZYME PHARMA
PVBC HIGHPEAK ENERGY INC (A)
SHYF PROVIDENT BANCORP INC
NRGX THE SHYFT GROUP INC
CYTH PIMCO ENERGY & TACTICAL CREDIT OPPORTUNITIES FUND
YELL CYCLO THERAPEUTICS
TCS YELLOW CORPORATION
RXST CONTAINER STORE GROUP
CMU INC.
JANX RXSIGHT INC
TTNP MFS HIGH YIELD MUNICIPAL TRUST
EMO JANUX THERAPEUTICS INC
MTEM TITAN PHARMACEUTICALS INC
ABOS CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
STCN MOLECULAR TEMPLATES
INC.
ACUMEN PHARMACEUTICALS
INC.
STEEL CONNECT INC
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees. On August 3, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to three new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 150,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(...
- Jonathan Moreland
PFSW PFSWEB INC
MPAA MOTORCAR PARTS OF AMERICA INC.
CVGW CALAVO GROWERS INC.
AQMS AQUA METALS INC
ACTG ACACIA RESEARCH CORP. - ACACIA TECHNOLOGIES
CULP CULP INC.
ENPH ENPHASE ENERGY INC.
TTC TORO COMPANY
GHC GRAHAM HOLDINGS CO.
SCWX SECUREWORKS
CDZI CADIZ INC.
SVRA SAVARA
PMM PUTNAM MANAGED MUNICIPAL INCOME TRUST
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
SMBC SOUTHERN MISSOURI BANCORP INC.
PMO PUTNAM MUNICIPAL OPPORTUNITIES TRUST
VBIV VBI VACCINES INC/BC
CVLY CODORUS VALLEY BANCORP INC.
OXSQ OXFORD SQUARE CAPITAL
SMAR SMARTSHEET
EVLO EVELO BIOSCIENCES
NHS NEUBERGER BERMAN HIGH YIELD ST
LARK LANDMARK BANCORP INC.
ZM ZOOM VIDEO COMMUNICATIONS
BW INC.
QMCO BABCOCK & WILCOX ENTERPRISES
BDTX QUANTUM CORP /DE/
ENX BLACK DIAMOND THERAPEUTICS
EPSN INC.
ZI EATON VANCE NEW YORK MUNICIPAL BOND FUND
PASG EPSILON ENERGY LIMITED
GRIL ZOOMINFO TECHNOLOGIES INC.
ACET PASSAGE BIO
ALVR INC.
HPK MUSCLE MAKER
MAX ADICET BIO INC
CLNN ALLOVIR
NRGX HIGHPEAK ENERGY INC (A)
RMBL MEDIAALPHA
JANX INC.
TTNP CLENE INC
EFSH PIMCO ENERGY & TACTICAL CREDIT OPPORTUNITIES FUND
MTEM RUMBLEON INC
OKE JANUX THERAPEUTICS INC
TITAN PHARMACEUTICALS INC
1847 HLDGS LLC
MOLECULAR TEMPLATES
INC.
ONEOK
INC.
- Jonathan Moreland
Savara Announces Pricing of $80 Million Underwritten Offering of Commo...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 21,000,000 shares of its common stock at a price of $3.00 per share and, in lieu of common stock to certain investors that so choose, 5,666,667 pre-funded warrants to purchase common stock at a price of $2.999 per pre-funded warrant, in each case before deducting underwriting discounts and commissions, for total gross proceeds of approximately $80 million. All of the securities to be sold in the offering a...
Savara Added to Russell 3000® Index
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has been added to the U.S. broad-market Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open on Monday, June 26, 2023. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of April 28, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in t...
Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgr...
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that enrollment has been completed for the pivotal Phase 3 IMPALA-2 trial. A total of 164 patients were randomized. Target enrollment for the trial was 160 patients. The Company expects to report top line results by the end of 2Q 2024. IMPALA-2 is a global, 48-week, placebo-controlled clinical trial evaluating molgramostim, a novel inhaled biologic, for the treatment of aPAP, a rare lung disease with no approved pharmacological treatments. “Enrollm...
Savara to Present at the Jefferies Healthcare Conference
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am ET/7:30 am PT. A live webcast of the fireside chat will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage co...
Savara Inc: 1 director
A director at Savara Inc bought 100,000 shares at 2.585USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Savara Reports First Quarter Financial Results and Provides Business U...
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2023 and provided a business update. “In June of this year, we expect the pivotal Phase 3 IMPALA-2 trial to be fully enrolled, therefore, we remain on-track to report top line safety and efficacy data by the end of 2Q 2024,” said Matt Pauls, Chair and CEO, Savara. “Importantly, we believe we are fully capitalized through 2025, which is about 18 months beyond the top line data readout.” First Quar...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On May 3, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 195,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 125,000 shares of the Company’s common stock. These equity awards w...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On March 29, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 30,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of ...
Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Pr...
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update. “Enrollment in the pivotal Phase 3 IMPALA-2 trial remains on-track, and we continue to anticipate reporting top line safety and efficacy data by the end of 2Q 2024,” said Matt Pauls, Chair and CEO, Savara. “As we approach the milestone of enrollment completion, I am proud of the team’s ability to advance the molgramostim development program duri...
Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 1:20pm ET. A live webcast of the presentation will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor...
Savara Announces New Employment Inducement Grant Under NASDAQ Listing ...
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On February 24, 2023, Savara's Board of Directors granted the inducement award to Robert M. Lutz, who joined the Company as Chief Operating Officer on February 13, 2023. The inducement award consists of options to purchase 350,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 140,000 shares of the Company’s common stock. This equity award was granted under the Savar...
Savara Announces New Leadership Appointments
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointments of two pharmaceutical industry veterans to its executive leadership team. Rob Lutz has been appointed Chief Operating Officer, effectively immediately. Scott Wilhoit was appointed Executive Vice President, Global Commercial, effective January 9, 2023, and Dave Lowrance was promoted from Chief Financial Officer to Chief Financial and Administrative Officer, effective December 13, 2022. “We are pleased that Rob and Scott, two seasone...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On January 17, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 195,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 60,000 shares of the Company’s common stock. These equity award...
- Jonathan Moreland
TSLA TESLA INC
RNG RINGCENTRAL INC. CLASS A
MACK MERRIMACK PHARMACEUTICALS INC
CAMP CALAMP CORP.
TZOO TRAVELZOO
ICD INDEPENDENCE CONTRACT DRILLING
CULP CULP INC.
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
MRAM EVERSPIN TECHNOLOGIES
JELD JELD-WEN HOLDING INC.
SVRA SAVARA
GTHX G1 THERAPEUTICS
LILA LIBERTY LATIN AMERICA A
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
LOVE LOVESAC
BYND BEYOND MEAT
FULC INC.
CMPR FULCRUM THERAPEUTICS
JYNT CIMPRESS PLC
HPK THE JOINT
PCVX HIGHPEAK ENERGY INC (A)
ONCR VAXCYTE
HQI ONCORUS
FET HIREQUEST INC.
PUBM FORUM ENERGY TECHNOLOGIES
ONDS PUBMATIC
LIXT ONDAS HOLDINGS
OLO LIXTE BIOTECHNOLOGY HOLDINGS
XMTR OLO
HYZN XOMETRY
AUGX INC.
LCID HYZON MOTORS INC.
JOBY AUGMEDIX
TBBK INC.
BLND LUCID GROUP INC
ROOT JOBY AVIATION INC
GLSI THE BANCORP
SNPX INC.
GCV ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
ROOT INC
GREENWICH LIFESCIENCES INC
SYNAPTOGENIX INC
THE GABELLI CONVERTIBLE AND INCOME SECURITIES FUND
INC.
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.